Oncology and Hematology - MedEd On The Go

Episodes 17-32 of 87

Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
MinuteCE®
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
0.75 credits 8 episodes
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 credits 8 episodes
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Diversity in HER2 Expression Among Gynecologic Cancers
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®
Diversity in HER2 Expression Among Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
CME/CE
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
0.50 credits
- Justin Gainor, MD
- Jacob Sands, MD
0.50 credits
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
MinuteCE®
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Managing Myelofibrosis-Associated Anemia
Managing Myelofibrosis-Associated Anemia
MinuteCE®
Managing Myelofibrosis-Associated Anemia
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit
How and When to Manage Ruxolitinib Failure
How and When to Manage Ruxolitinib Failure
MinuteCE®
How and When to Manage Ruxolitinib Failure
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Improving Transfusion Independence With JAK Inhibitor Therapy
Improving Transfusion Independence With JAK Inhibitor Therapy
MinuteCE®
Improving Transfusion Independence With JAK Inhibitor Therapy
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
MinuteCE®
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit
Real-World Experience With Pacritinib in the US
Real-World Experience With Pacritinib in the US
MinuteCE®
Real-World Experience With Pacritinib in the US
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
MinuteCE®
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
1.00 program credit
- John Mascarenhas, MD
- Gabriela Hobbs, MD
1.00 program credit
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
MinuteCE®
Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit

2/6